Compare VHC & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | NTRB |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Industrial Specialties |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 71.7M |
| IPO Year | 1999 | N/A |
| Metric | VHC | NTRB |
|---|---|---|
| Price | $22.03 | $4.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 14.6K | ★ 20.3K |
| Earning Date | 11-14-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $106,000.00 | ★ $2,578,059.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | N/A | $3,394.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2020.00 | 42.92 |
| 52 Week Low | $3.68 | $3.72 |
| 52 Week High | $29.00 | $11.78 |
| Indicator | VHC | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 40.25 |
| Support Level | $18.21 | $4.45 |
| Resistance Level | $23.70 | $5.25 |
| Average True Range (ATR) | 1.92 | 0.33 |
| MACD | -0.33 | 0.07 |
| Stochastic Oscillator | 56.77 | 51.61 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.